1500 related articles for article (PubMed ID: 20143189)
41. E2F-1: a proliferative marker of breast neoplasia.
Zhang SY; Liu SC; Al-Saleem LF; Holloran D; Babb J; Guo X; Klein-Szanto AJ
Cancer Epidemiol Biomarkers Prev; 2000 Apr; 9(4):395-401. PubMed ID: 10794484
[TBL] [Abstract][Full Text] [Related]
42. Genomic differences between pure ductal carcinoma in situ of the breast and that associated with invasive disease: a calibrated aCGH study.
Iakovlev VV; Arneson NC; Wong V; Wang C; Leung S; Iakovleva G; Warren K; Pintilie M; Done SJ
Clin Cancer Res; 2008 Jul; 14(14):4446-54. PubMed ID: 18628458
[TBL] [Abstract][Full Text] [Related]
43. Positive enhancement integral values in dynamic contrast enhanced magnetic resonance imaging of breast carcinoma: ductal carcinoma in situ vs. invasive ductal carcinoma.
Nadrljanski M; Maksimović R; Plešinac-Karapandžić V; Nikitović M; Marković-Vasiljković B; Milošević Z
Eur J Radiol; 2014 Aug; 83(8):1363-7. PubMed ID: 24894697
[TBL] [Abstract][Full Text] [Related]
44. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
[TBL] [Abstract][Full Text] [Related]
45. Expression of manganese superoxide dismutase in patients with breast cancer.
Tsai SM; Hou MF; Wu SH; Hu BW; Yang SF; Chen WT; Chai CY; Ma H; Tsai LY
Kaohsiung J Med Sci; 2011 May; 27(5):167-72. PubMed ID: 21527182
[TBL] [Abstract][Full Text] [Related]
46. Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study.
Ottesen GL
APMIS Suppl; 2003; (108):1-67. PubMed ID: 12874968
[TBL] [Abstract][Full Text] [Related]
47. Abnormal expression of Nek2 and β-catenin in breast carcinoma: clinicopathological correlations.
Wang S; Li W; Lv S; Wang Y; Liu Z; Zhang J; Liu T; Niu Y
Histopathology; 2011 Oct; 59(4):631-42. PubMed ID: 22014044
[TBL] [Abstract][Full Text] [Related]
48. Is there different correlation with prognostic factors between "non-mass" and "mass" type invasive ductal breast cancers?
Jiang L; Zhou Y; Wang Z; Lu X; Chen M; Zhou C
Eur J Radiol; 2013 Sep; 82(9):1404-9. PubMed ID: 23540946
[TBL] [Abstract][Full Text] [Related]
49. Improved outcomes of breast-conserving therapy for patients with ductal carcinoma in situ.
Halasz LM; Sreedhara M; Chen YH; Bellon JR; Punglia RS; Wong JS; Harris JR; Brock JE
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):e581-6. PubMed ID: 22208975
[TBL] [Abstract][Full Text] [Related]
50. Recognizing breast ductal carcinoma in situ on fine-needle aspiration: a diagnostic dilemma.
Guo HQ; Zhang ZH; Zhao H; Zhao LL; Pan QJ
Diagn Cytopathol; 2013 Aug; 41(8):710-5. PubMed ID: 23729369
[TBL] [Abstract][Full Text] [Related]
51. Costimulatory molecule OX40/OX40L expression in ductal carcinoma in situ and invasive ductal carcinoma of breast: an immunohistochemistry-based pilot study.
Xie F; Wang Q; Chen Y; Gu Y; Mao H; Zeng W; Zhang X
Pathol Res Pract; 2010 Nov; 206(11):735-9. PubMed ID: 20634005
[TBL] [Abstract][Full Text] [Related]
52. Nudix-type motif 2 in human breast carcinoma: a potent prognostic factor associated with cell proliferation.
Oka K; Suzuki T; Onodera Y; Miki Y; Takagi K; Nagasaki S; Akahira J; Ishida T; Watanabe M; Hirakawa H; Ohuchi N; Sasano H
Int J Cancer; 2011 Apr; 128(8):1770-82. PubMed ID: 20533549
[TBL] [Abstract][Full Text] [Related]
53. S100A7 (psoriasin) expression is associated with aggressive features and alteration of Jab1 in ductal carcinoma in situ of the breast.
Emberley ED; Alowami S; Snell L; Murphy LC; Watson PH
Breast Cancer Res; 2004; 6(4):R308-15. PubMed ID: 15217497
[TBL] [Abstract][Full Text] [Related]
54. 99mTc-(V)DMSA scintimammography in the assessment of breast lesions: comparative study with 99mTc-MIBI.
Papantoniou V; Christodoulidou J; Papadaki E; Valotassiou V; Stipsanelli A; Louvrou A; Lazaris D; Sotiropoulou M; Pampouras G; Keramopoulos A; Michalas S; Zerva C
Eur J Nucl Med; 2001 Jul; 28(7):923-8. PubMed ID: 11504092
[TBL] [Abstract][Full Text] [Related]
55. Clonal alteration of breast cancer receptors between primary ductal carcinoma in situ (DCIS) and corresponding local events.
Karlsson E; Sandelin K; Appelgren J; Zhou W; Jirström K; Bergh J; Wärnberg F
Eur J Cancer; 2014 Feb; 50(3):517-24. PubMed ID: 24275214
[TBL] [Abstract][Full Text] [Related]
56. Immunohistological localisation of human FAT1 (hFAT) protein in 326 breast cancers. Does this adhesion molecule have a role in pathogenesis?
Kwaepila N; Burns G; Leong AS
Pathology; 2006 Apr; 38(2):125-31. PubMed ID: 16581652
[TBL] [Abstract][Full Text] [Related]
57. Id4 messenger RNA and estrogen receptor expression: inverse correlation in human normal breast epithelium and carcinoma.
de Candia P; Akram M; Benezra R; Brogi E
Hum Pathol; 2006 Aug; 37(8):1032-41. PubMed ID: 16867866
[TBL] [Abstract][Full Text] [Related]
58. Association between tumor size and immunohistochemical expression of Ki-67, p53 and BCL2 in a node-negative breast cancer population selected from a breast cancer screening program.
González-Sistal A; Sánchez AB; Del Rio MC; Arias JI; Herranz M; Ruibal A
Anticancer Res; 2014 Jan; 34(1):269-73. PubMed ID: 24403473
[TBL] [Abstract][Full Text] [Related]
59. Inhibin/activin subunits (inhibin-alpha, -betaA and -betaB) are differentially expressed in human breast cancer and their metastasis.
Mylonas I; Jeschke U; Shabani N; Kuhn C; Friese K; Gerber B
Oncol Rep; 2005 Jan; 13(1):81-8. PubMed ID: 15583806
[TBL] [Abstract][Full Text] [Related]
60. Investigation of immunohistochemical ERα, ERβ and ERβcx expressions in normal and neoplastic breast tissues.
Bozkurt KK; Kapucuoğlu N
Pathol Res Pract; 2012 Mar; 208(3):133-9. PubMed ID: 22336175
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
